Vyvgart Iv MG denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for vyvgart iv mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step Therapy to Vyvgart (efgartigimod alfa) IV

Step therapy — sometimes called "fail first" — requires that a patient try and fail one or more less expensive or more established treatments before the plan will authorize a specialty biologic like Vyvgart. For generalized myasthenia gravis, UHC's step therapy protocol typically requires documentation of an adequate trial of conventional immunosuppressive or symptomatic therapies before approving efgartigimod IV. A denial here means UHC believes the step has not been adequately documented.

## Why This Denial Is Appealable

Step therapy policies are subject to clinical override when a required step drug is contraindicated, was previously tried and failed, or poses unacceptable risk to the specific patient. Many states have enacted step therapy reform laws that require insurers to grant exceptions in these circumstances. Even under ERISA-governed self-funded plans, a well-documented exception request can succeed.

## Your Federal and State Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): Submit within the deadline stated in the denial letter. Include clinical documentation of all prior therapies and any exception criteria.
• Step-therapy exception: Specifically invoke the plan's step-therapy exception procedure, which UHC is required to have. Common exception grounds: prior trial of the required drug; contraindication; clinical urgency; rapid disease progression.
• External review: After final internal denial, request IRO review. The external review window is approximately four months from the final internal decision.
• Expedited review: Available for urgent clinical situations — decisions typically within 72 hours.

## Documentation to Gather

1. Prior therapy log: A complete, dated list of every previously tried treatment for the condition, including dosages attempted, duration of each trial, and the reason the trial ended (inefficacy, intolerance, or contraindication). 2. Failure documentation: Chart notes, lab results, or clinical assessments that objectively document treatment failure or intolerance for each required step. 3. Exception grounds letter: The prescribing neurologist should write a letter explaining why the step-therapy requirement should be waived — citing the specific exception criterion that applies (e.g., prior trial and failure, clinical contraindication, or urgency). 4. Current clinical status: Recent functional assessments showing the patient's current disease severity and the risk of delaying Vyvgart.

## Criteria-Mapping Structure

Obtain UHC's step therapy criteria for Vyvgart IV from the provider portal or the denial letter. List each required step. For every step, document either (a) the date, duration, and outcome of the patient's trial of that therapy, or (b) the clinical reason it was not appropriate for this patient. Presenting this as a structured table leaves no ambiguity for the reviewer.

## Practical Note

If the patient already completed the required step therapies but the PA submission lacked adequate documentation, the appeal is essentially a documentation correction — gather the records and resubmit with the complete prior therapy history.